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Creutzfeldt-Jakob disease1. Introduction
Transmissible spongiform encephalopathies, also called ‘prion dis-
eases,’ are caused by abnormally accumulated prion protein (PrP-res)
in the central nervous system (CNS). The causative agent is thought to
be solely composed of amyloid prion proteins and is not inactivated
by standard and popular procedures. Iatrogenic Creutzfeldt-Jakob dis-
ease (CJD) can be caused by the reuse of neurosurgical instruments or
contamination of biomaterials, such as dura mater graft material
(Thadani et al., 1988; Bernoulli et al., 1977; Will & Matthews, 1982).
However, extensive investigations have concluded that accidental
prion transmission, as well as sporadic CJD (sCJD), which is the idio-
pathic form of CJD, is not likely the consequence of spontaneous somatic
mutations. The proteinase K (PK)-resistant (PK-res) PrP in sCJD has
been shown to be limited to cases with biological materials from theehabilitation Science, Nagasaki
Sakamoto, Nagasaki 852-8501,
h).
. This is an open access article underCNS or cornea. Additionally, in sCJD, prion infectivity has not been de-
tected in extracerebral organs in studies using animal models, suggest-
ing that infectious prions are restricted to the CNS. However, recent
studies used Western blotting analysis to detect PrP-res in the spleen
of a sCJD patient, although the PrPSc levels were lower by a factor of ap-
proximately 10−4 than in brain tissue (Glatzel et al., 2003). These stud-
ies highlight the need to elucidate prion distribution in humans to
reduce the risk of accidental prion infection. Various studies have al-
ready detected PK-resistant PrP in peripheral tissues in natural and ex-
perimental sCJD cases. For instance, GlatzelM, et al. (Glatzel et al., 2003)
used Western blotting to show the presence of PrPSc in the spleen, as
well as in the muscle of some sCJD patients. Additionally, Rubenstains
et al. detected PrPSc in tonsil and lymph node tissues of sCJD patients
(Rubenstein & Chang, 2013). Experimentally, Herzog et al. infected non-
human primates with the sCJD agent (among others) to investigate the
involvement of peripheral organs (Herzog et al., 2005). They also con-
ﬁrmed the presence of PrPSc in lymphoreticular organs and muscles.
A technique recently developed for in vitro ampliﬁcation of prions,
the RT-QuIC (quaking-induced conversion) assay, is a highly sensitive
and speciﬁc technique that can detect small amounts of prion-seedingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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RT-QuIC assay was approximately 0.12 fg of PrP-res (Herzog et al.,
2005). Combined with an endpoint dilution, it was possible to quantify
prion-seeding activity and the 50% seeding dose (SD50), which correlat-
ed well with PK-res PrP. These results encouraged us to re-evaluate the
human prion in various tissues in sCJD patients.
2. Materials & Methods
2.1. Patients
A total of four female patients were diagnosed with classical-type
sCJD, which was histopathologically conﬁrmed after autopsy. To avoid
contamination of brain tissue, other organs were separately harvested.
The tissue specimens were immediately stored at−80 °C until further
use. Western blotting analysis of the PK-res PrP fragment and genotyp-
ing at codon 129 of the PRNP gene was conducted as previously de-
scribed by the reference laboratory of the Japan CJD Surveillance Unit.
Non-CJD tissues were purchased from Proteo Genex (Culver City, CA,Fig. 1. Analysis of brain tissues frompatients with sporadic CJD using bioassay and endpoint RT-
ChM mice inoculated with a serially diluted brain homogenate from Patient #1. (B) Endpoin
represents the percentage of occurrence of symptoms caused by prion disease. (C, D) Endpo
endpoint RT-QuIC assay was used to evaluate prion-seeding activity. (D) Each value repres
performed in triplicate for each sample. (E) Endpoint RT-QuIC assay of brain tissues frompatientUSA). The protocol was approved by the Ethics Committee of Nagasaki
University Hospital (ID: 100428423) and the use of specimens was
also granted ethical approval by the Japan CJD Surveillance Unit. The
study was registered with the University Hospital Medical Information
Network (ID: UMIN000003301). Informed consent was obtained from
patient families and/or patients.
2.2. Tissue Homogenate Preparation
Brains, spleens, kidneys, lungs, livers, and adrenal glands were sub-
jected to RT-QuIC for evaluating SD50. To prevent contamination of
brain tissues into other samples, we used single-use disposable tubes
and beads, and all procedures were performed on different days. Tissue
samples of brain, spleen, kidney, lung, liver, and adrenal gland were
homogenized in 10% (w/v) ice-cold phosphate-buffered saline supple-
mentedwith a protease inhibitormixture (Roche,Mannheim, Germany)
using a multi-bead shocker (Yasui Kikai, Osaka, Japan). The samples
were clariﬁed by centrifugation at 6000 rpm for 2 min and stored at
−80 °C.QuIC assay. (A, B) Transmission of human prions to Ki-ChMmice. (A) Survival curve for Ki-
t titration of brain tissue from a sCJD patient (Patient #1) using the bioassay. Each value
int RT-QuIC assay of brain tissue from Patient #1. (C) Brain tissue was diluted and the
ents the percentage of positive reactions for each dilution rate. The experiments were
swith sCJD (Patients #2–4). The experimentswere performed in triplicate for each sample.
152 H. Takatsuki et al. / EBioMedicine 12 (2016) 150–1552.3.Western Blotting of Precipitated PrPSc Collected Using the Ultra-Centrif-
ugal Concentration Method in Tissues of Sporadic CJD Patients and the
Heathy Subjects
Brain (1 mg) or tissue (100 mg) homogenates from normal persons
or CJD patients were lysed in the same volume of 2× cell lysis buffer
(100 mM Tris-HCl at pH 7.5, 300 mMNaCl, 1% Triton X-100, 1% sodium
deoxycholate). Samples were digested with PK concentration (ﬁnial
concentration) at 50 μg/ml and incubated at 37 °C for 30 min. After
that, samples were mixed with 4 mM pefabloc SC (Roche) to inactivate
PK. The tissue homogenates (100mg) were centrifuged at 6000 rpm for
3 min to remove cell debris. The supernatants (1 ml) from tissues were
transferred to the bottom of a 5-ml ultra-centrifuge tube and 4 ml of
phosphate-buffered saline (PBS) was overlaid. The samples were
ultra-centrifuged at 100,000 ×g at room temperature for 1 h. After cen-
trifugation, the supernatants were removed and the pellets were re-
suspended with sample buffer and boiled at 95 °C for 10 min. The sam-
ples were separated to SDS-polyacrylamide gel electrophoresis (PAGE)
and transferred onto a PVDF membrane (Millipore) in transfer bufferFig. 2. Endpoint RT-QuIC assay of non-neuronal tissues. Homogenates of spleen, kidney, live
performed in triplicate (three sets of four wells). Each value represents the percentage of positcontaining 20% methanol. The proteins were blocked with 5% skim
milk in TBS-T for 60 min. To detect PrP, the membrane was incubated
with anti-PrP antibody (3F4, primary antibody) and anti-mouse IgG an-
tibody conjugated with horseradish peroxidase (HRP) as the secondary
antibody. The PrP-reswere imaged using enhanced chemiluminescence
(ECL)-plus reagents (Amersham) and a CCD camera gel imager (ATTO).
2.4. Endpoint RT-QuIC (Takatsuki et al., 2015; Wilham et al., 2010)
Puriﬁcation of recombinant human PrP (rHuPrP: residues 23–231,
codon 129 M) was performed as previously described (Takatsuki et
al., 2015). After puriﬁcation, rHuPrP was stored at−80 °C. Brain ho-
mogenates (BHs) (10% [w/v]) were serially diluted (10-fold) with arti-
ﬁcial cerebrospinal ﬂuid (A-CSF) containing 125 mM NaCl, 2.5 mM
KCl, 2mMCaCl2, 1mMMgCl2, 0.2 ng/ml BSA, and0.05% glucose. rHuPrP,
suspended in 95 μl of RT-QUIC buffer (500 mM NaCl, 50 mM PIPES
pH 7.0, 10 μM Thioﬂavin T (ThT), and1 mM EDTA), was loaded into
each well of a 96-well plate and mixed with 5 μl of brain sample, and
then the assay was monitored for 40 h. Four to eight replicates of eachr, lung, and adrenal gland were diluted and applied to the assay. The experiments were
ive reactions in four wells.
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153H. Takatsuki et al. / EBioMedicine 12 (2016) 150–155diluted sample were measured. The SD50 was calculated using the
Spearman–Kärber method. The same organs from two healthy subjects
were used as negative controls in all RT-QuIC assay experiments using
eight wells.
2.5. Bioassay
To evaluate the 50% lethal dose (LD50) in a brain sample from a sCJD
patient (#1), we conducted a bioassay using a knock-in transgenic mice
expressing the human-mouse chimeric PrP (Ki-ChM mouse) (Taguchi
et al., 2003). The Ki-ChM mouse line was kindly provided by Dr.
Kitamoto and his colleagues and was maintained in our institute. At
4 weeks of age, the Ki-ChM mice were intracerebrally inoculated with
20 μl of brain homogenate, following a serial dilution with PBS, into
the right parietal lobe. All animal experiments were approved by the
committee of Nagasaki University in accordance with the Guidelines
for Animal Experimentation of Nagasaki University and conformed to
the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health.
2.6. PrP-Immunohistochemistry in Extra-Neural Tissues of sCJD Patients
and the Heathy Subjects
Formalin-ﬁxed brain tissues were treated with formic acid (99% for
human tissues or 60% for mouse tissues) for 1 h to inactivate the infec-
tivity, and embedded in parafﬁn. Tissue sections were pretreated by hy-
drolytic autoclaving before PrP-immunohistochemistry. The anti-PrP
monoclonal antibody 3F4 (Signet, Dedham, MA, USA) was used as the
primary antibody for human sections, and anti-PrP antiserum PrP-N
was used as the primary antibody for mouse sections. Goat-anti-
mouse immunoglobulin polyclonal antibody labeled with peroxidase-
conjugated dextran polymer, EnVision+ (Dako), and anti-rabbit
EnVision + were used as secondary antibodies.
2.7. Phosphotungstic Acid Precipitation (PTA)
We performed the concentration of PrPSc according to previous re-
ports (Glatzel et al., 2003).
3. Results
3.1. Analysis of Brain Tissues from Patients with Sporadic CJD the Heathy
Subjects by Bioassay and Endpoint RT-QuIC Assay (Fig. 1)
Ki-ChMmice inoculated with 10−1 to 10−4 diluted sCJD brain sam-
ples developed symptoms; incubation periods were 150 ± 5 days,
193 ± 7 days, 197 ± 6 days, and 243 ± 23 days, respectively (Fig. 1A,
B). The Ki-ChM mice inoculated with 10−5 diluted sCJD brain samples
for N400 days all survived. The incubation time was N330 days in mice
treated with 10−5 diluted sCJD (Fig. 1A, B). The prion-seeding activity
of this sample was also evaluated. As shown in Fig. 1C and D, 100% pos-
itive reactions were seen in 5 × 10−5 and 5 × 10−6 dilutions; the posi-
tive rate dropped to 75% in the 5 × 10−7 dilution. Following inoculation
with the 5 × 10−8 dilution, there were no signals within 40 h, so the
SD50 was calculated as 1010.25/g tissue. The SD50 of other samples was
also determined as shown in Fig. 1E. All samples exhibited a similar
level of seeding activity (109.17–10.25/g). In all samples from the healthy
subjects, the RT-QuIC reaction remained unchanged and maintained a
baseline within 48 h.
3.2. Analysis of Extra-Neural Tissues from sCJD Patients the Heathy Subjects
UsingEndpoint RT-QuICAssay,WesternBlotting, andPrP-Immunohistochemistry
The homogenized samples of ﬁve different organs showed positive
reactions in RT-QuIC, except for one liver sample from Patient #2. Fol-
lowing inoculation of spleen and lung tissues from Patient #3, positive
154 H. Takatsuki et al. / EBioMedicine 12 (2016) 150–155signalswere only detected in onewell out of 12, so it was not possible to
determine the amount of prion activity in this endpoint assay (Fig. 2).
Several positive samples, such as liver and adrenal gland tissues from
Patient #1, did not exhibit 100% positivity in repeated tests, so we
were not able to determine the SD50. In the remaining 14 samples,
100% of positive replicates were observed at 5 × 10−2 to 5 × 10−4 dilu-
tions. And all samples of ﬁve different organs in the heathy subjects, the
RT-QuIC reaction remained unchanged andmaintained a baselinewith-
in 48 h. The SD50 values were calculated and are summarized in Table 1.
We could not detect PrP-res in tissues of sCJD patients and healthy
control subjects by Western blotting or PrP-immunohistochemistry
using standard protocols (data not shown), but concentration by cen-
trifugal separation allowed detection of PrP-res in tissues of sCJD pa-
tients (Fig. 3). And we were not able to detect the PrP-res in tissues of
sCJD patients by PTA concentration (not data shown). This method en-
abled the concentration of PrP-res to N103 times that allowed by the
standard method.
4. Discussion
Prion-seeding activity in tissues from sCJD patients was evaluated
using the endpoint RT-QuIC assay, which revealed an unexpectedly
wide distribution of prion activity in all tested patients. The SD50 valuesµ µµ
µ µµ
Fig. 3.Western blotting analysis of PrP-res in tissue from sporadic CJD patients using the concen
or tissue (100mg of weight) homogenates, such as spleen, kidney, adrenal gland, liver, or lung f
lower panel), were digestedwith PK and samples were prepared forWestern blotting (seeMate
on SDS-PAGE, and PrPSc was detected using anti-PrP (3F4) monoclonal antibody and anti-mo
Western blotting. The rate indicates measured band intensity, which was compared with bra
compared between concentration (C) and standard (S) method. PK-digested samples direc
(N.D.: Not detected.)reached approximately 106/g in extra-neural organs. With the excep-
tion of a single adrenal gland (Patient #2), we were not able to detect
PrP-res using theWestern blotting assay with PTA. We also did not ob-
serve abnormal PrP-immunopositivity on tissue sections. However, this
could be due to prion-seeding activities in non-neuronal tissues that
were 10,000 times lower than in brain tissues.
The RT-QuIC assaywas approximately 104 timesmore sensitive than
the bioassay using knock-in mice expressing a human-mouse chimeric
PrP (Fig. 1), although the SD50 was reported to be 100 times greater
than the LD50 of 263 K hamster prions (Atarashi et al., 2011). Because
the prion-seeding activity in kidney tissues of sCJD patients was 105.5–
6.25/g, for example, infectivity (LD50) could be 101.5/g in the organ. This
is an extremely low level of infectivity compared with CNS infections.
However, it should not be overlooked that prion activity could become
detectable in peripheral organs, because human prion disease can de-
velop even after a 30–40-year incubation period (Collinge et al., 2006).
Additionally, the tissue volume was 103–4 greater than the human
brain volume, and PrP-res in non-neuronal tissues was 103–4 greater
than in the brain. Ourmethod allowed detection of PrP-res in the spleen
of Patient #2 (Fig. 3). The SD50 in the Patient #2 brain (SD50: 9.42)was
103–4 greater than the SD50 in the spleen of Patient #2 (SD50: 6.25).
Therefore, our method successfully concentrated tissues by approxi-
mately 103–4 greater than standard Western blotting.25
20
µ µµ
trationmethod, which precipitates the sample by centrifugal separation. The brain (1mg)
romnormal persons (a–b, upper panel) or sporadic CJD patient 2 (a, lower panel) and 4 (b,
rials andMethods). The tissues (100mg) and brain (1, 10, or 100 μg) sampleswere loaded
use IgG antibody-conjugated HRP. The brain samples were used as a detection limit for
in samples. Recombinant human PrP is used as expose control. c) Detection limits were
tly mixed with sample buffer in standard methods, which loaded to indicating weight.
155H. Takatsuki et al. / EBioMedicine 12 (2016) 150–155Expression of physiological PrP in the human body has been well
studied. PrPC is expressed in almost all tissues, although mRNA expres-
sion levels are highest in the CNS; the spleen and liver are 1/20 of the
cortex, the lungs are 1/10, and the kidneys and adrenal glands are 1/5
(The Genotype-Tissue Expression (GTEx) project, 2013; Uhlen et al.,
2015). PrP-res has been detected in the spleen and muscles of some
sCJD patients byWestern blotting analysis when PrP-res in the samples
was concentrated by PTA (Glatzel et al., 2003). However, we cannot ig-
nore the possibility that seeding activities detected in peripheral tissues
are a result of infectious agents overﬂowing from the CNS, because re-
sults show that kidneys and adrenal glands can be infected and produce
abnormal PrP in situ. This study is the ﬁrst to identify prion-seeding ac-
tivities in the kidney or liver, and we may have to collect organs from
pre-symptomatic CJD patients. The highly sensitive RT-QuIC assay may
be useful for providing safer methods and techniques when using
human materials.
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